Author: [AUTHOR] Published on 6/1/2020 12:00:00 AM
Jan‐Stefan van der Walt, MBBS, Principal Scientist, Eli Lilly, and Company, Windlesham, United Kingdom
Dr. van der Walt describes his career path as “a little atypical for most pharmacometricians.” He worked as a medical practitioner before becoming a pharmacometrician. He describes ASCPT as a “safe haven for unicorns – an organization that appreciates people with diverse and unique skill sets.”
The ASCPT family of journals are Dr. van der Walt’s go‐to journals. When he lived in South Africa, he did not realize that there was a Society behind the excellent Clinical Pharmacology & Therapeutics (CPT ) and CPT: Pharmacometrics & Systems Pharmacology (CPT:PSP ) journals. At the University of Cape Town, he always selected an article from CPT for their weekly journal club and he also convinced some of his colleagues to submit manuscripts to CPT .
In 2015, Dr. Stacey Tannenbaum convinced Dr. van der Walt to attend his first ASCPT meeting in New Orleans. Five years later, he still remembers the QSP pre‐conference held during that Annual Meeting and the “TED”‐style presentations it offered. As a pharmacometrician based in the United Kingdom, he rarely has the opportunity to attend scientific meetings in the United States. However, the online content for members and the reduced fee for the Annual Meeting has made membership with ASCPT attractive. He looks forward to running into many former colleagues from the Pharmacometrics Group at Uppsala University or from Astellas at future meetings.
Dr. van der Walt is interested in exploring the different Communities that are supported by ASCPT, especially the Development, Regulatory, & Outcomes (DRO) Network where the quantitative pharmacology may be underutilized but have a lot to offer.
Dr. van der Walt believes that the impact he now has on patient care is less tangible than when he was a healthcare provider, but he feels the impact is on a larger scale. He believes that “we all know someone whose health has benefitted from one or more medicines that we helped to develop or bring to the market.” Currently, one of his main research interests is the effects of drug‐disease interactions on efficacy and safety.
Dr. van der Walt has been a member of ASCPT since 2020.